Table 3 Treatment parameters
Parameters | Total | |
|---|---|---|
Absolute (n) | Relative (%) | |
Treatment sequence | ||
Upfront EBRT | 58 | 67 |
Upfront SBT | 28 | 33 |
SBT | Median (range) | |
Reference dose (Gy) | 54.0 (20.0–60.0) | |
Dose rate (cGy/h) | 10.0 (5.0–22.0) | |
Tumor volume (ccm) | 3.56 (0.22–50.50) | |
Treatment time (h) | 500 (200–1044) | |
BED for late reacting tissue (Gy3) | 46.88 (17.40–72.89) | |
BED for tumor tissue (Gy10) | 41.59 (15.50–63.14) | |
Number of implanted seeds/patient | Number of patients | |
1 | 39 | 45 |
2 | 34 | 40 |
3 | 11 | 13 |
4 | 2 | 2 |
EBRT | Median (range) | |
Treatment time (days) | 43 (20–67) | |
Dose of single fraction (Gy) | 2.0 (1.60–2.67) | |
Total dose (Gy) | 60.0 (40.05–69.40) | |
BED for late reacting tissue (Gy3) | 73.6 (55.44–91.11) | |
BED for tumor tissue (Gy10) | 45.6 (34.27–54.49) | |
Cumulative BED after EBRT + SBT | Median (range) | |
Total BED for late reacting tissue (Gy3) | 120.38 (83.73–180.92) | |
Total BED for tumor tissue (Gy10) | 87.23 (54.02–130.16) | |
Interval between EBRT and SBT (months) | Median (range) 19 (2–227) | |
Systemic treatment simultaneous to re-irradiation | ||
Yes | 11 | 13 |
Temozolomide | 11 | 100 |
No | 69 | 80 |
Unknown | 6 | 7 |
Systemic treatment sequential after re-irradiation (within 1 year) | ||
Yes | 30 | 35 |
Temozolomide | 17 | 57 |
Temozolomide → Bevacizumab | 1 | 3 |
Temozolomide → PCV | 1 | 3 |
PC | 1 | 3 |
PC → Bevacizumab/Irinotecan | 1 | 3 |
Bevacizumab | 2 | 7 |
Bevacizumab/Irinotecan | 3 | 10 |
Bevacizumab/PC | 1 | 3 |
Bevacizumab/Temozolomide | 3 | 10 |
No | 49 | 57 |
Unknown | 7 | 8 |
Sequential bevacizumab after re-irradiation (within 1 year) | ||
Yes | 11 | 13 |
No | 68 | 79 |
Unknown | 7 | 8 |